Overview

Low INR to Minimize Bleeding With Mechanical Valves Trial

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.
Phase:
Phase 3
Details
Lead Sponsor:
McMaster University
Population Health Research Institute
Collaborator:
Hamilton Health Sciences Corporation
Treatments:
Warfarin